United Therapeutics (UTHR) Lower As Analyst Highlights Sandoz Generic Remodulin Filing
Tweet Send to a FriendGet Alerts UTHR Hot Sheet
Price: $68.47 --0%
Rating Summary:
3 Buy, 13 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 8
Rating Summary:
3 Buy, 13 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 8
Trade UTHR Now!
Shares of United Therapeutics Corp. (NASDAQ: UTHR) are lower in early action Tuesday after an analyst at Deutsche Bank highlighted that Sandoz has filed an ANDA to make generic remodulin.
The firm notes that "Sandoz states it intends to market a generic version of Remodulin before the expiration of US 5,153,222, US 6,765,117, and US 7,999,007 patents in 2014, 2017, and 2029, Sandoz states thes patents are not valid/enforceable and/or will not be infringed by the commercial manufacture," of their ANDA product."
The '117 patent appears to be a product by process patent, and maybe the key patent keeping a generic off the market before 2018, the analyst notes.
Past analysis from the firm suggests that if a generic launches in 2014 the fair value of UTHR is ~$38/share and if after 2018 the fair value is ~$48/share.
The firm maintained their Hold and $53 price target on UTHR.
For an analyst ratings summary and ratings history on United Therapeutics Corp. click here. For more ratings news on United Therapeutics Corp. click here.
Shares of United Therapeutics Corp. last traded at $49.84, down 2.3%.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm notes that "Sandoz states it intends to market a generic version of Remodulin before the expiration of US 5,153,222, US 6,765,117, and US 7,999,007 patents in 2014, 2017, and 2029, Sandoz states thes patents are not valid/enforceable and/or will not be infringed by the commercial manufacture," of their ANDA product."
The '117 patent appears to be a product by process patent, and maybe the key patent keeping a generic off the market before 2018, the analyst notes.
Past analysis from the firm suggests that if a generic launches in 2014 the fair value of UTHR is ~$38/share and if after 2018 the fair value is ~$48/share.
The firm maintained their Hold and $53 price target on UTHR.
For an analyst ratings summary and ratings history on United Therapeutics Corp. click here. For more ratings news on United Therapeutics Corp. click here.
Shares of United Therapeutics Corp. last traded at $49.84, down 2.3%.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Merck's (MRK) Suvorexant Faces Challenges at FDA
- Goldman Sachs Maintains Sell on Microsoft (MSFT)
- Dougherty & Co Raises PT on SodaStream (SODA) to $80
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Deutsche Bank
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
